Milestone Pharmaceuticals
MIST
47 hedge funds and large institutions have $199M invested in Milestone Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 2 closing their positions.
950% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 2
62% more funds holding
Funds holding: 29 → 47 (+18)
56% more capital invested
Capital invested by funds: $127M → $199M (+$71.5M)
27% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $9.09M
3.63% more ownership
Funds ownership: 69.58% → 73.21% (+3.6%)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
+$18.4M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.12M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$4.81M |
| 4 |
LPC
Lion Point Capital
New York
|
+$4.62M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$11.7M |
| 2 |
O
OrbiMed
New York
|
-$11.2M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.02M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.97M |
| 5 |
Millennium Management
New York
|
-$3.23M |
MIST Hedge Fund Activity: Q3 2022 in Review
47 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q3 2022, worth a combined $199M — up 56% from $127M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MIST positions and 2 closed out — a net gain of 19 holders — while 9 added to existing stakes and 12 trimmed.
The largest buyer was VR Adviser, opening a new position worth an estimated $18.4M. The largest seller was Boxer Capital, cutting an estimated $11.7M.
- 47 institutional investors held Milestone Pharmaceuticals (MIST) as of Q3 2022, up from 29 in Q2 2022.
- Funds reported $199M of Milestone Pharmaceuticals stock for Q3 2022, up 56% quarter-over-quarter.
- 21 funds opened new Milestone Pharmaceuticals positions in Q3 2022 and 2 closed out, a net change of +19 holders.
- The largest Milestone Pharmaceuticals buyer in Q3 2022 was VR Adviser, an estimated $18.4M added.
- The largest Milestone Pharmaceuticals seller in Q3 2022 was Boxer Capital, an estimated $11.7M sold.
Based on aggregated 13F filings for Q3 2022.